SANTONI, Mauro
 Distribuzione geografica
Continente #
EU - Europa 238
NA - Nord America 227
AS - Asia 74
Totale 539
Nazione #
US - Stati Uniti d'America 219
IT - Italia 81
CN - Cina 25
FR - Francia 25
SE - Svezia 22
SG - Singapore 19
GB - Regno Unito 18
IN - India 17
IE - Irlanda 15
NL - Olanda 14
DE - Germania 9
VN - Vietnam 8
BA - Bosnia-Erzegovina 6
GR - Grecia 6
PL - Polonia 6
CA - Canada 5
SI - Slovenia 5
UA - Ucraina 5
ES - Italia 4
RS - Serbia 4
CH - Svizzera 3
HR - Croazia 3
ID - Indonesia 3
MX - Messico 3
AT - Austria 2
DK - Danimarca 2
FI - Finlandia 2
ME - Montenegro 2
RO - Romania 2
IL - Israele 1
KR - Corea 1
PT - Portogallo 1
RU - Federazione Russa 1
Totale 539
Città #
Chandler 35
Santa Clara 27
Fairfield 21
Dublin 15
Singapore 14
Milan 13
Amsterdam 12
Torino 11
Houston 10
Nyköping 8
Ashburn 7
Rome 7
Banja Luka 6
London 6
Paris 6
Preveza 6
Wilmington 6
Beijing 5
Chaponost 5
Mumbai 5
Munich 5
Pisa 5
Seattle 5
Turin 5
Belgrade 4
Brookline 4
Columbus 4
Dong Ket 4
Jacksonville 4
Newcastle upon Tyne 4
Princeton 4
Cambridge 3
Chengdu 3
Chennai 3
Coyoacán 3
Genay 3
Hyderabad 3
Jakarta 3
Redwood City 3
Stockholm 3
Toulouse 3
Vancouver 3
Warsaw 3
Woodbridge 3
Zagreb 3
Andover 2
Ann Arbor 2
Atlanta 2
Bengaluru 2
Birmingham 2
Celje 2
Dossobuono 2
Flanders 2
Fuzhou 2
Genoa 2
Hangzhou 2
Helsinki 2
Lake Villa 2
Lenart v Slov. Goricah 2
Lucca 2
Madrid 2
Messina 2
New Delhi 2
New York 2
Nuremberg 2
Padova 2
Philadelphia 2
Phoenixville 2
Pomezia 2
San Francisco 2
Sevenoaks 2
Shenzhen 2
Tarbes 2
Vejle 2
Westfield 2
Woodstock 2
Altopascio 1
Aosta 1
Boston 1
Brooklyn 1
Calgary 1
Cardito 1
Cluj-Napoca 1
Coventry 1
Dearborn 1
Duncan 1
Eindhoven 1
Frattamaggiore 1
Funchal 1
Geneva 1
Guiyang 1
Hebei 1
Hefei 1
Hellikon 1
Kettering 1
Krakow 1
Lancaster 1
Ljubljana 1
Mannheim 1
Medford 1
Totale 401
Nome #
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 276
The beam and Detector of the NA62 experiment at CERN 110
Emotion and Knowledge in Decision Making under Uncertainty 103
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes 58
Totale 547
Categoria #
all - tutte 1.561
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.561


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202011 0 0 0 0 0 1 3 0 1 1 2 3
2020/202166 3 4 7 1 4 4 3 4 9 11 6 10
2021/202281 0 8 10 1 8 4 3 9 0 12 23 3
2022/2023185 11 17 6 12 14 31 17 17 28 16 9 7
2023/2024120 9 28 14 9 12 11 7 11 1 11 4 3
2024/202563 1 3 5 7 35 12 0 0 0 0 0 0
Totale 547